Child-Pugh Score Calculator

What Is the Child-Pugh Score?

The Child-Pugh score (also known as the Child-Pugh-Turcotte score or Child-Turcotte-Pugh score) is one of the most widely used clinical tools for assessing the prognosis of chronic liver disease, particularly cirrhosis. It was originally developed by Dr. C.G. Child and Dr. J.G. Turcotte in 1964 as a way to predict outcomes following portosystemic shunt surgery for portal hypertension. Their initial classification system included five clinical and biochemical parameters to stratify patients into three categories of increasing severity.

In 1973, Dr. R.N.H. Pugh and colleagues modified the original Child-Turcotte classification by replacing the nutritional status parameter with the prothrombin time (later adapted to use INR), making the scoring system more objective and reproducible. This modified version—known as the Child-Pugh score—has since become one of the cornerstones of hepatology practice worldwide.

The score ranges from 5 to 15 points, with five parameters each contributing 1 to 3 points. Patients are classified into one of three classes: Class A (well-compensated disease, 5–6 points), Class B (significant functional compromise, 7–9 points), or Class C (decompensated disease, 10–15 points). The Child-Pugh classification is used in numerous clinical contexts, including determining eligibility for liver transplantation, predicting surgical risk, guiding medication dosing adjustments, and estimating overall prognosis.

The Five Components Explained in Detail

Each of the five parameters in the Child-Pugh score reflects a different aspect of liver function. Understanding what each component measures and why it is included provides essential context for interpreting the overall score.

1. Total Bilirubin

Bilirubin is a yellowish pigment produced during the normal breakdown of red blood cells. The liver processes (conjugates) bilirubin so it can be excreted in bile. When the liver is damaged or cirrhotic, it becomes less efficient at conjugating and excreting bilirubin, leading to elevated levels in the blood. This manifests clinically as jaundice—yellowing of the skin and eyes.

In the Child-Pugh scoring system, total bilirubin is measured in mg/dL (or μmol/L). A level below 2 mg/dL (34 μmol/L) indicates relatively preserved hepatic excretory function and scores 1 point. Levels between 2–3 mg/dL (34–50 μmol/L) suggest moderate impairment (2 points), while levels above 3 mg/dL (50 μmol/L) reflect significant hepatic dysfunction (3 points).

Bilirubin is considered one of the most important markers of liver synthetic and excretory function. Persistently elevated bilirubin levels in cirrhotic patients are associated with worse outcomes and higher mortality rates. It is also a key component of the MELD score, which is used for organ allocation in liver transplantation.

2. Serum Albumin

Albumin is the most abundant protein in the blood, produced exclusively by the liver. It plays a critical role in maintaining oncotic pressure (which prevents fluid from leaking out of blood vessels), transporting hormones, fatty acids, and drugs, and serving as a buffer for acid-base balance. The half-life of albumin is approximately 20 days, making it a useful marker for chronic (rather than acute) liver function.

In patients with cirrhosis, the liver's ability to synthesize albumin decreases progressively. Low albumin levels (hypoalbuminemia) contribute to ascites formation and peripheral edema. In the Child-Pugh system, albumin above 3.5 g/dL indicates relatively preserved synthetic function (1 point), levels between 2.8–3.5 g/dL suggest moderate impairment (2 points), and levels below 2.8 g/dL reflect severe synthetic failure (3 points).

3. INR (International Normalized Ratio)

The INR measures how long it takes for blood to clot, standardized across different laboratories and testing reagents. It is derived from the prothrombin time (PT) test. The liver synthesizes most of the clotting factors (including factors I, II, V, VII, IX, and X), so when liver function deteriorates, coagulation is impaired and the INR rises.

In the original Child-Turcotte classification, prothrombin time prolongation (in seconds above normal) was used. The Pugh modification, and subsequently modern practice, uses the INR for better standardization. An INR below 1.7 suggests relatively preserved coagulation function (1 point), values between 1.7–2.3 indicate moderate impairment (2 points), and an INR above 2.3 reflects severe coagulopathy (3 points). Elevated INR in cirrhotic patients increases the risk of bleeding complications, particularly from varices.

4. Ascites

Ascites refers to the pathological accumulation of fluid within the peritoneal (abdominal) cavity. It is one of the most common complications of cirrhosis and portal hypertension. The pathophysiology involves a combination of increased portal pressure, low albumin (reduced oncotic pressure), sodium and water retention due to activation of the renin-angiotensin-aldosterone system, and splanchnic vasodilation.

In the Child-Pugh score, ascites is graded clinically: none (1 point), mild or controlled with diuretic medications (2 points), and moderate to severe or refractory to treatment (3 points). Refractory ascites—defined as ascites that cannot be mobilized or that recurs early despite sodium restriction and maximal diuretic therapy—carries a particularly poor prognosis, with a median survival of approximately 6 months without liver transplantation.

It is worth noting that ascites assessment is somewhat subjective, which is one of the recognized limitations of the Child-Pugh score. Physical examination findings can vary between clinicians, and small-volume ascites may only be detectable by ultrasound.

5. Hepatic Encephalopathy

Hepatic encephalopathy (HE) is a spectrum of neuropsychiatric abnormalities caused by liver insufficiency and/or portosystemic shunting. When the liver fails to adequately detoxify substances absorbed from the gut—most notably ammonia—these toxins reach the brain and alter neurotransmitter function. Symptoms range from subtle cognitive impairment and sleep disturbances (minimal HE or Grade I) to asterixis and confusion (Grade II), somnolence and gross disorientation (Grade III), and coma (Grade IV).

In the Child-Pugh system, hepatic encephalopathy is scored as: none (1 point), Grade I–II or controlled with medication such as lactulose or rifaximin (2 points), and Grade III–IV or refractory (3 points). Like ascites, the grading of hepatic encephalopathy involves a degree of clinical subjectivity, particularly in distinguishing between Grade I and minimal HE. Several psychometric tests (such as the Psychometric Hepatic Encephalopathy Score) and the EncephalApp Stroop test can help with standardized assessment.

Complete Child-Pugh Scoring Table

The following table summarizes all five parameters and their scoring criteria. Each parameter contributes 1, 2, or 3 points, and the total score ranges from a minimum of 5 (best liver function) to a maximum of 15 (worst liver function).

Child-Pugh Classification: Class A, B, and C

Based on the total score, patients are classified into three groups that have distinct prognostic implications.

Class A (5–6 points): Well-Compensated Disease

Patients in Class A have well-compensated cirrhosis with minimal or no clinical decompensation. Liver synthetic function is largely preserved, and there are typically no signs of ascites or encephalopathy (or these are minimal). The 1-year survival rate for Class A patients is approximately 100%, and the 2-year survival rate is approximately 85%. Perioperative mortality for abdominal surgery is estimated at about 10%.

Class A patients generally tolerate surgical procedures well and may not require immediate liver transplant evaluation. However, they still need regular monitoring for disease progression, variceal development, and hepatocellular carcinoma screening.

Class B (7–9 points): Significant Functional Compromise

Class B represents moderate hepatic impairment. These patients often have clinically apparent ascites, mildly elevated bilirubin, reduced albumin, or some degree of encephalopathy. The 1-year survival rate drops to approximately 81%, with a 2-year survival rate of approximately 57%. Perioperative mortality increases substantially to about 30%.

Patients in Class B require careful consideration before any surgical procedure. Elective surgeries are generally approached with caution, and referral for liver transplant evaluation is often appropriate, especially if there is evidence of ongoing deterioration. Medication dosing may need adjustment, and nutritional support becomes increasingly important.

Class C (10–15 points): Decompensated Disease

Class C represents decompensated cirrhosis with severe hepatic dysfunction. These patients typically have significant jaundice, refractory ascites, recurrent or severe hepatic encephalopathy, and coagulopathy. The 1-year survival rate is only approximately 45%, and the 2-year survival rate is approximately 35%. Perioperative mortality is very high at approximately 82%, making most elective surgeries prohibitively risky.

Class C patients are usually evaluated urgently for liver transplantation if they are otherwise suitable candidates. Medical management focuses on controlling complications (large-volume paracentesis for ascites, lactulose/rifaximin for encephalopathy, variceal band ligation or TIPS for recurrent bleeding), and palliative care discussions may be appropriate in some cases.

Clinical Applications

The Child-Pugh score is used across a wide range of clinical scenarios in hepatology, surgery, and pharmacology.

Liver Transplant Listing

Although the MELD score has largely replaced the Child-Pugh score for organ allocation prioritization in many countries (including the United States since 2002), the Child-Pugh classification is still used in some transplant centers worldwide and remains important for initial evaluation and communication among clinicians. A Child-Pugh score of 7 or greater (Class B or C) often triggers referral for transplant evaluation.

Surgical Risk Assessment

The Child-Pugh classification is one of the primary tools used to estimate perioperative risk in cirrhotic patients undergoing surgery. As noted above, perioperative mortality ranges from approximately 10% for Class A to over 80% for Class C. This information is critical for surgical planning, informed consent discussions, and determining whether to proceed with, defer, or cancel elective procedures. Emergency surgery in cirrhotic patients carries even higher mortality regardless of Child-Pugh class.

Medication Dosing Adjustments

Many drugs are metabolized by the liver, and impaired hepatic function can lead to drug accumulation and toxicity. The Child-Pugh classification is specifically referenced in the prescribing information of numerous medications to guide dose adjustments. For example, certain benzodiazepines, opioids, beta-blockers, and antifungal agents have specific dosing recommendations for Child-Pugh Class A, B, and C patients. The FDA frequently requires pharmacokinetic studies stratified by Child-Pugh class as part of drug development programs.

TIPS Procedure Eligibility

Transjugular intrahepatic portosystemic shunt (TIPS) is a procedure used to manage complications of portal hypertension, including refractory ascites and recurrent variceal bleeding. The Child-Pugh score helps assess whether a patient is likely to benefit from TIPS or is at high risk of post-TIPS hepatic encephalopathy and liver failure. Generally, TIPS is considered cautiously in patients with Child-Pugh scores above 11–12, as the risk of precipitating liver failure increases substantially.

Prognosis Communication

The Child-Pugh classification provides a straightforward, easy-to-understand framework for communicating disease severity to patients and their families. The classification into three classes with associated survival estimates facilitates discussions about prognosis, treatment goals, and advance care planning.

Child-Pugh vs. MELD Score

The Model for End-Stage Liver Disease (MELD) score is another widely used prognostic tool in hepatology. While both the Child-Pugh and MELD scores assess liver disease severity, they differ in several important ways.

The MELD score's continuous scale provides better discrimination between patients, which is essential for fair organ allocation. However, the Child-Pugh score's inclusion of ascites and encephalopathy means it captures important clinical dimensions that MELD does not. In practice, both scores are often used complementarily. The Child-Pugh score is particularly useful for surgical risk stratification and drug dosing guidance, while the MELD score is the standard for transplant prioritization.

Limitations of the Child-Pugh Score

Despite its widespread use and proven clinical utility, the Child-Pugh score has several recognized limitations that clinicians should be aware of.

• Subjectivity: Two of the five components—ascites and hepatic encephalopathy—are assessed clinically and involve a degree of subjective judgment. Different clinicians may grade the same patient differently, leading to inter-observer variability. Minimal ascites detectable only by imaging, for instance, may be classified as "none" by one clinician and "mild" by another.
• Ceiling and Floor Effects: The score has a limited range (5–15), and each parameter can only contribute 1, 2, or 3 points. This means that extreme laboratory abnormalities (e.g., bilirubin of 20 mg/dL vs. 4 mg/dL) are assigned the same score of 3 points, even though the clinical implications may be quite different. This lack of granularity limits the score's discriminative ability at the extremes.
• Categorical Rather Than Continuous: Patients are grouped into three classes, which means that a patient with a score of 7 (low Class B) and a patient with a score of 9 (high Class B) receive the same classification, despite potentially significant differences in disease severity.
• No Renal Component: The Child-Pugh score does not include any measure of renal function, which is a significant limitation because hepatorenal syndrome and renal impairment are common in advanced cirrhosis and strongly associated with mortality. The MELD score addresses this by including creatinine.
• Arbitrary Cutoff Points: The specific cutoff values for each parameter (e.g., bilirubin < 2, 2–3, > 3 mg/dL) were originally established based on limited data and clinical judgment rather than rigorous statistical analysis. While they have proven clinically useful over decades, they may not be optimal for all patient populations.
• Equal Weighting: All five parameters are weighted equally (each contributing 1–3 points), but in reality, some parameters may be more prognostically significant than others. For example, bilirubin and INR may carry more weight than ascites in predicting mortality, but this is not reflected in the scoring system.
• Etiology Not Considered: The Child-Pugh score does not account for the underlying cause of liver disease. The prognosis and treatment options may differ significantly between, for example, alcohol-related cirrhosis, viral hepatitis, and autoimmune hepatitis, but the score treats all etiologies the same.

Understanding Liver Cirrhosis

Cirrhosis is the end stage of chronic liver disease characterized by widespread fibrosis (scarring) and the formation of regenerative nodules, which disrupt the normal architecture and function of the liver. It develops over years to decades and is typically irreversible by the time it reaches an advanced stage. The liver is a remarkably resilient organ with significant regenerative capacity, but chronic and sustained injury eventually overwhelms this ability.

Major Causes of Cirrhosis

• Alcohol-Related Liver Disease: Chronic heavy alcohol consumption is one of the most common causes of cirrhosis worldwide. Alcohol is directly toxic to hepatocytes (liver cells), causing a spectrum of damage from fatty liver (steatosis) to alcoholic hepatitis to cirrhosis. The risk increases with the duration and quantity of alcohol consumption. Women are generally more susceptible than men at lower consumption levels.
• Chronic Hepatitis B (HBV): HBV is a major global cause of cirrhosis, particularly in Asia and Africa. Chronic HBV infection causes ongoing liver inflammation, which drives fibrosis progression. Antiviral therapy (e.g., tenofovir, entecavir) can suppress viral replication and slow or halt fibrosis progression, but cirrhosis cannot always be reversed once established.
• Chronic Hepatitis C (HCV): HCV was historically one of the leading causes of cirrhosis and liver transplantation. The development of direct-acting antivirals (DAAs) since 2014 has revolutionized treatment, achieving cure rates above 95%. However, patients who already have established cirrhosis remain at risk for complications and hepatocellular carcinoma even after viral cure.
• Non-Alcoholic Fatty Liver Disease (NAFLD) / Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): With the rising global prevalence of obesity, metabolic syndrome, and type 2 diabetes, NAFLD/MASLD has become the fastest-growing cause of cirrhosis. Non-alcoholic steatohepatitis (NASH), the progressive form of NAFLD, involves inflammation and hepatocyte damage that can lead to fibrosis and cirrhosis over time.
• Autoimmune Hepatitis: An immune-mediated inflammatory condition in which the body's immune system attacks hepatocytes. Without treatment (typically immunosuppressive therapy with corticosteroids and azathioprine), it can progress to cirrhosis.
• Primary Biliary Cholangitis (PBC) and Primary Sclerosing Cholangitis (PSC): These are chronic cholestatic liver diseases that damage bile ducts and can lead to cirrhosis.
• Hereditary Conditions: Hemochromatosis (iron overload), Wilson disease (copper accumulation), and alpha-1 antitrypsin deficiency can all cause chronic liver damage and cirrhosis.
• Drug-Induced Liver Injury: Chronic exposure to certain medications (e.g., methotrexate, isoniazid) can cause progressive liver damage.

Liver Function Tests Explained

Liver function tests (LFTs) are a group of blood tests commonly used to assess the health and function of the liver. Understanding these tests is essential for interpreting the Child-Pugh score and monitoring liver disease progression.

Tests Reflecting Liver Damage (Hepatocellular Injury)

• ALT (Alanine Aminotransferase): An enzyme found predominantly in the liver. Elevated ALT levels suggest hepatocyte damage. ALT is more specific to the liver than AST. Normal range is typically 7–56 U/L.
• AST (Aspartate Aminotransferase): Found in the liver, heart, muscle, and other tissues. Elevated AST may indicate liver damage but is less specific than ALT. The AST/ALT ratio can help distinguish between different causes of liver disease (e.g., a ratio > 2 suggests alcohol-related liver disease).

Tests Reflecting Cholestasis (Bile Flow Impairment)

• ALP (Alkaline Phosphatase): Elevated levels suggest bile duct obstruction or intrahepatic cholestasis. ALP is also found in bone, so elevated levels can have non-hepatic causes. Normal range is typically 44–147 U/L.
• GGT (Gamma-Glutamyl Transferase): Often elevated in cholestatic liver disease and with alcohol use. It helps confirm that an elevated ALP is of hepatic origin.

Tests Reflecting Liver Synthetic Function

• Albumin: As discussed above, albumin is produced by the liver and reflects chronic synthetic capacity. Low albumin indicates impaired liver function.
• PT/INR: The liver produces clotting factors, so prolonged prothrombin time (elevated INR) indicates impaired synthetic function.
• Total Bilirubin: Reflects the liver's ability to process and excrete bilirubin. Elevated levels indicate either increased production (hemolysis), impaired conjugation, or impaired excretion.

Treatment Options for Liver Disease by Severity

Management of chronic liver disease varies significantly based on the underlying cause, the degree of fibrosis, and the Child-Pugh classification.

Compensated Cirrhosis (Child-Pugh A)

• Etiology-specific treatment: Antiviral therapy for hepatitis B/C, alcohol abstinence for alcohol-related disease, immunosuppression for autoimmune hepatitis, phlebotomy for hemochromatosis, etc.
• Surveillance: Regular screening for hepatocellular carcinoma (HCC) with ultrasound every 6 months, endoscopic screening for esophageal varices, and monitoring of liver function tests.
• Lifestyle modifications: Alcohol avoidance, healthy diet, weight management, exercise, and vaccination against hepatitis A and B if not already immune.
• Beta-blockers: Non-selective beta-blockers (e.g., propranolol, nadolol, carvedilol) for primary prophylaxis of variceal bleeding in patients with medium-to-large varices.

Moderately Decompensated Cirrhosis (Child-Pugh B)

• All measures listed above for compensated disease.
• Ascites management: Sodium restriction (typically < 2,000 mg/day), diuretic therapy (spironolactone +/- furosemide), and therapeutic paracentesis for tense ascites.
• Encephalopathy management: Lactulose (to reduce ammonia absorption) and rifaximin (antibiotic to reduce ammonia-producing gut bacteria).
• Nutritional support: Adequate caloric intake (35–40 kcal/kg/day), protein supplementation (1.2–1.5 g/kg/day, contrary to older recommendations of protein restriction), and late-evening snacks to reduce overnight catabolism.
• Transplant evaluation: Referral to a transplant center for assessment of candidacy.

Severely Decompensated Cirrhosis (Child-Pugh C)

• All measures listed above, with intensified management.
• Liver transplantation: The definitive treatment for end-stage liver disease. Transplant evaluation is urgent for Class C patients.
• TIPS: May be considered for refractory ascites or recurrent variceal bleeding, but carries significant risks in patients with very high Child-Pugh scores.
• Palliative care: For patients who are not transplant candidates, palliative care focuses on symptom management, quality of life, and advance care planning.
• SBP prophylaxis: Prophylactic antibiotics (e.g., norfloxacin) for patients with low ascitic fluid protein to prevent spontaneous bacterial peritonitis.

When to Seek Medical Attention

Patients with known or suspected liver disease should seek immediate medical attention if they experience any of the following symptoms or signs:

• New or worsening jaundice (yellowing of the skin or whites of the eyes)
• Increasing abdominal swelling (ascites) or sudden onset of abdominal distension
• Confusion, drowsiness, or personality changes (may indicate hepatic encephalopathy)
• Vomiting blood or passing black, tarry stools (may indicate variceal or other gastrointestinal bleeding)
• Fever or chills in the setting of known ascites (may indicate spontaneous bacterial peritonitis)
• Significantly decreased urine output (may indicate hepatorenal syndrome)
• Rapid weight gain (fluid retention)
• Persistent nausea, vomiting, or inability to eat

Frequently Asked Questions (FAQ)